MBX Biosciences (MBX) Total Current Liabilities (2023 - 2026)
MBX Biosciences (MBX) reported Total Current Liabilities of $14.6 million for Q1 2026, up 38.98% on a YoY basis from $10.5 million in Q1 2025, and down 5.99% sequentially from $15.5 million in Q4 2025.
MBX Biosciences (MBX) Total Current Liabilities (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Total Current Liabilities data on file, last reported at $14.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 38.98% year-over-year to $14.6 million; the trailing twelve-month figure through Mar 2026 stood at $14.6 million (up 38.98% YoY), and the FY2025 full-year result was $15.5 million, up 40.21% from the prior year.
- Total Current Liabilities retreated to $14.6 million in Q1 2026, from $15.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $15.5 million in Q4 2025 to a low of $3.9 million in Q4 2023.
- A 4-year average of $11.3 million and a median of $11.4 million in 2024 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 181.48% in 2024 and rose 10.46% in 2025, its largest moves.
- Tracing MBX's Total Current Liabilities over 4 years: stood at $3.9 million in 2023, then surged by 181.48% to $11.1 million in 2024, then soared by 40.21% to $15.5 million in 2025, then decreased by 5.99% to $14.6 million in 2026.
- Business Quant data shows MBX's Total Current Liabilities at $14.6 million in Q1 2026, $15.5 million in Q4 2025, and $12.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | MBX Biosciences | 2.96 Bn | 2.96 Bn | - | 14.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.57 Mn |
| Dec 31, 2025 | 15.50 Mn |
| Sep 30, 2025 | 12.06 Mn |
| Jun 30, 2025 | 11.76 Mn |
| Mar 31, 2025 | 10.48 Mn |
| Dec 31, 2024 | 11.05 Mn |
| Sep 30, 2024 | 10.92 Mn |
| Dec 31, 2023 | 3.93 Mn |